New and updated preclinical and clinical data presented by biopharma firms at the Society for Immunotherapy of Cancer’s annual meeting Nov. 9-14, including: Adaptimmune, Alligator, Amphivena, Anaveon, Bolt, Checkmate, Cue, Dcprime, Elicio, Evelo, Exicure, F-star, Ikena, I-Mab, Immatics, Immutep, IMV, Infinity, Istari, Leap, Medigene, Nanobiotix, Neoleukin, Nkarta, Onconano, Phio, Repertoire, Sensei, Seven and Eight, Surface Oncology, Xencor.